Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Pipeline Review, H1 2016

Description: Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Pipeline Review, H1 2016

Summary

‘Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Pipeline Review, H1 2016’, provides in depth analysis on Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) targeted pipeline therapeutics.

The report provides comprehensive information on the Respiratory Syncytial Virus Fusion Protein (RSV-F Protein), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Respiratory Syncytial Virus Fusion Protein (RSV-F Protein)
- The report reviews Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) targeted therapeutics and enlists all their major and minor projects
- The report assesses Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Respiratory Syncytial Virus Fusion Protein (RSV-F Protein)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents:

List of Tables
List of Figures
Introduction
Report Coverage
Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Overview
Therapeutics Development
Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Products under Development by Stage of Development
Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Products under Development by Therapy Area
Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Products under Development by Indication
Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Products under Development by Companies
Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Products under Development by Universities/Institutes
Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Companies Involved in Therapeutics Development
Ablynx NV
Agilvax, Inc.
Aridis Pharmaceuticals LLC
Bavarian Nordic A/S
Celltrion, Inc.
Emergent BioSolutions Inc.
F. Hoffmann-La Roche Ltd.
Gene Techno Science Co., Ltd.
GenVec, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
iBio, Inc.
Johnson & Johnson
mAbxience S.A.
MedImmune, LLC
Medivir AB
Mucosis B.V.
Navigen Pharmaceuticals, Inc.
Novavax, Inc.
Regeneron Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
The International Biotechnology Center (IBC) Generium
Vaxart, Inc.
VLP Biotech, Inc.
Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Drug Profiles
(human parainfluenza virus [serotype 1] + respiratory syncytial virus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(influenza (virus like particle) + respiratory syncytial virus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AK-0529 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALX-0171 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AR-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GNR-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GV-2311 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-61187165AAA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-61187191AAA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-7510 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-8897 - Drug Profile
Product Description
Product Description

Mechanism Of Action

R&D Progress

presatovir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus (virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus (virus like particle) vaccines - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

respiratory syncytial virus vaccine - Drug Profile
RV-521 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Respiratory Syncytial Virus Fusion Protein for RSV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
suptavumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SynGEM - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit RSV-F Protein for RSV Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Dormant Projects
Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Discontinued Products
Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Featured News & Press Releases
Jun 02, 2016: Novavax Announces New Seasonal Combination Respiratory Vaccine Program
May 25, 2016: U.S. FDA Grants Fast Track Designation to Novavax RSV F Vaccine for Older Adults
May 23, 2016: Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations
May 03, 2016: Ablynx reports positive top line results for its inhaled Anti-RSV Nanobody (ALX-0171) in a phase I/IIa Study in infants hospitalised with a RSV infection
Mar 09, 2016: First consortium of local manufacturers to make affordable biosimilars available for low income countries
Mar 04, 2016: Immune Design's GLAAS Platform Shown to Modulate the Allergic Immune Response
Jan 20, 2016: Mucosis Secures €3.7M from Wellcome Trust to Fund Clinical Trials of its Respiratory Syncytial Virus Vaccine in Partnership with Imperial College London
Dec 21, 2015: Novavax Appoints Mark Twyman Vice President Marketing

Dec 17, 2015: Ablynx Completes Enrollment Of The First-In-Infant Phase I/IIa Safety Study With Its Anti-RSV Nanobody And Extends The Trial For Younger Infants

Dec 14, 2015: Novavax Completes Enrollment of Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults

Dec 03, 2015: Novavax Initiates Global Pivotal Phase 3 Trial of the RSV F Vaccine to Protect Infants via Maternal Immunization

Nov 19, 2015: Vaxart Presents Positive Preclinical Data for Oral RSV Vaccine at RSV Vaccines for the World Conference

Nov 16, 2015: Novavax to Make Multiple Presentations at RSV Vaccines for the World

Nov 09, 2015: Novavax Initiates Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults

Oct 29, 2015: MEDI7510 for Respiratory Syncytial Virus Advances to Phase 2 Leverages Immune Design's GLAAS Discovery Platform

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by Ablynx NV, H1 2016
Pipeline by Agilvax, Inc., H1 2016
Pipeline by Aridis Pharmaceuticals LLC, H1 2016
Pipeline by Bavarian Nordic A/S, H1 2016
Pipeline by Celltrion, Inc., H1 2016
Pipeline by Emergent BioSolutions Inc., H1 2016
Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
Pipeline by Gene Techno Science Co., Ltd., H1 2016
Pipeline by GenVec, Inc., H1 2016
Pipeline by Gilead Sciences, Inc., H1 2016
Pipeline by GlaxoSmithKline Plc, H1 2016
Pipeline by iBio, Inc., H1 2016
Pipeline by Johnson & Johnson, H1 2016
Pipeline by mAbxience S.A., H1 2016
Pipeline by MedImmune, LLC, H1 2016
Pipeline by Medivir AB, H1 2016
Pipeline by Mucosis B.V., H1 2016
Pipeline by Navigen Pharmaceuticals, Inc., H1 2016
Pipeline by Novavax, Inc., H1 2016
Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016
Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016
Pipeline by Vaxart, Inc., H1 2016
Pipeline by VLP Biotech, Inc., H1 2016
Dormant Projects, H1 2016
Discontinued Products, H1 2016 108
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3788913/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3788913/
Office Code: SCBR2HSZ

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td>USD 3500</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
</tr>
<tr>
<td>Site License:</td>
<td>USD 7000</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td>USD 10500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr</th>
<th>Mrs</th>
<th>Dr</th>
<th>Miss</th>
<th>Ms</th>
<th>Prof</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Last Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World